FY2025 · ended Dec 31, 2025 · Revenue $31.37M, -27.5% YoY · Filed Mar 5, 2026
EyePoint, Inc. (EYPT) files with the SEC under industry code 3826, Laboratory Analytical Instruments. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $31.4 million and a net loss of $232.0 million. Free cash flow was -$243.4 million. As of Jun 30, 2026 it held $180.5 million in cash and investments and $22.4 million in total debt.
Revenue (TTM)
$2.79M
-94.6% vs year-ago TTM
Net income (TTM)
$-306.64M
-74.8% vs year-ago TTM
Operating cash flow (TTM)
$-267.30M
-40.3% vs year-ago TTM
Free cash flow (TTM)
$-271.28M
-39.8% vs year-ago TTM
EPS (TTM)
$-3,768.35
-38.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
83.43M
+21.4% vs prior year
Net cash
$158.10M
as of Jun 30, 2026
Operating margin
-11369.3%
FY 2026
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- EYPT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1314102
- Former names
- EyePoint Pharmaceuticals, Inc. (until Dec 8, 2025); pSivida Corp. (until Mar 30, 2018); pSivida LTD (until Jun 18, 2008)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M | $36.9M |
| Operating income | -$243.4M | -$145.9M | -$75.1M | -$99.6M | -$55.3M |
| Net income | -$232.0M | -$130.9M | -$70.8M | -$102.3M | -$58.4M |
| Diluted EPS | -$3.17 | -$2.32 | -$1.82 | -$2.74 | — |
| Operating cash flow | -$240.1M | -$126.2M | $1.9M | -$65.0M | -$50.1M |
| Free cash flow | -$243.4M | -$130.3M | -$1.6M | -$67.2M | -$50.3M |
| Total assets | $364.0M | $418.5M | $355.2M | $180.4M | $263.4M |
| Total liabilities | $57.9M | $82.0M | $88.9M | $84.0M | $79.0M |
| Stockholders' equity | $306.1M | $336.5M | $266.3M | $96.4M | $184.4M |
| Cash and investments | $306.1M | $370.9M | $331.1M | $144.6M | $211.6M |
| Total debt | $22.8M | $23.1M | $5.5M | $47.0M | $39.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Other events
|
Oct 19, 2026 | Oct 17, 2026 |
| 8-K |
Current report
Other events
|
Oct 19, 2026 | Oct 19, 2026 |
| 8-K |
Current report
Other events
|
Sep 10, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Other events
|
Aug 17, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
All 1001 EyePoint, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.